Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Hemorrhagic Hereditary Telangiectasia with Severe Hepatic Vascular Malformations
NCT00843440Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2009
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Hospices Civils de Lyon. Started Mar 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT00843440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843440.